source
- Spruce Biosciences advances toward Q4 FDA filing for ultra-rare Sanfilippo B therapySpruce Biosciences reported progress toward filing its enzyme replacement therapy, tralesinidase alfa (TA-ERT), for Sanfilippo syndrome type B, an ultra-rare lysosomal disorder. The company said t…
- FDA clears Roche and Lilly Alzheimer’s blood tests, while Regenxbio gene therapy trial halted againThe U.S. Food and Drug Administration announced it has granted clearance for blood-based diagnostic tests for Alzheimer’s disease developed by Roche and Eli Lilly. The clearances allow the compani…